Jon and Pete Najarian on Board Biotech Entrepreneur and Cannabis Investment Specialist

The Najarian brothers of CNBC fame have welcomed two new members to the strategic advisory team of Innovation Shares’ Cannabis ETF (THCX).

The ETF, which launched in July, will add Stable Road Capital CIO, Brian Kabot, and healthcare and biotechnology entrepreneur, Neal Patel, Ph.D. In response, Matt Markiewicz, Managing Director of Innovation Shares said Thursday the new additions will bolster awareness of the fund.

“The Najarian brothers have been renowned investors over the past three decades. With the addition of both Dr. Patel and Brian Kabot, we have deepened our bench of cannabis experts,” Markiewicz said in a press release.

“We are excited to add not only such a high level of institutional investment acumen but a brilliant scientific and medical perspective as well. In addition to providing ongoing counsel for Innovation Shares’ strategic direction, our esteemed team of strategic advisors will help us leverage fresh perspectives in order to expand THCX’s presence in investors’ portfolios.”

Who is Joining the Najarian Brothers at THCX?

The two new additions bring a wealth of experience and knowledge to the fund, according to Markiewicz.

First, Kabot is the CIO of Stable Road Capital, where he specializes in cannabis investing and in the operation of businesses, assets, and funds. Prior to this role, he was Founding Partner of the event-driven fund, Riverloft Capital.

Meanwhile, Dr. Patel is a doctor and biotechnology entrepreneur in the pharmaceutical and medical cannabis spaces. He has previously developed clinical protocols for firms like Sanofi, Regeneron, Pfizer, Bayer AG, Novartis, and GlaxoSmithKline. He is the Founder and Principal of Tendaji Ventures.

According to the press release, Dr. Patel’s early-stage incubator develops research partnerships between biotech and pharmaceutical companies that want to expand into the medical cannabis industry.

The additions come at an exciting time for the fund’s development. The Najarian brothers believe cannabis could be one of the best investments over the next few decades.

“Over the years I’ve been drawn to investing in disruptive industries and I believe that cannabis is in the very early innings of what could prove to be a generational investment opportunity,” said Jon Najarian.

About The Cannabis ETF (THCX)

Finally, the Cannabis ETF (THCX) tracks the Innovation Labs Cannabis Index.

The index consists of 35 stocks. Should the global cannabis market continue to expand and remain profitable, these stocks would appreciate in value.

Due to the expected expansion in legal and medical cannabis, Jon Najarian said in the same Forbes interview that he believes THCX will become a $1 billion ETF.

According to documents around the fund, the ETF rebalances each month. Because of the monthly rebalancing, Peter Najarian told Forbes that THCX is much different than typical cannabis funds.

“The fund resets each month, giving us a better pure-play because we are not going to get trapped in the same dog-chasing-the-tail clawbacks,” Pete Najarian said in an interview.

He warned that other ETFs may trap investors by holding certain stocks for two to three months. These funds, he says, do so regardless of whether they are performing or underperforming.